Vanguard Portfolio Management
FATE icon

Vanguard Portfolio Management’s Fate Therapeutics FATE Stock Holding History

Vanguard Portfolio Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.8M Buy
4,959,037
+413,144
+9% +$1.07M ﹤0.01% 2108
2026
Q2 		$12.3M Buy
4,545,893
+411,308
+10% +$761K ﹤0.01% 2133
2026
Q1 		$4.96M Buy
+4,134,585
New +$5.03M ﹤0.01% 2323

Other funds holding FATE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Vanguard Portfolio Management's FATE Position: Q3 2026 in Review

Vanguard Portfolio Management increased its Fate Therapeutics (FATE) stake by 9.1% in Q3 2026, buying an estimated $1.07M and bringing the position to 4,959,037 shares worth $11.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2108.

Vanguard Portfolio Management first reported a position in FATE in Q1 2026 and has held it in 3 quarters since. The position peaked at $12.3M in Q2 2026. 101 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • Vanguard Portfolio Management held 4,959,037 shares of Fate Therapeutics worth $11.8M as of Q3 2026.
  • Vanguard Portfolio Management bought 413,144 Fate Therapeutics shares in Q3 2026, an estimated $1.07M.
  • Fate Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #2108 holding.
  • Vanguard Portfolio Management first reported a position in Fate Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Portfolio Management's Fate Therapeutics position peaked at $12.3M in Q2 2026.
  • 101 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.